Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion

Leukemia

Volumn 15, Issue 10, 2001, Pages 1572-1581

  Plenchette, S ^a   Moutet, M ^a   Benguella, M ^b   N'Gondara, J P ^b   Guigner, F ^b   Coffe, C ^b   Corcos, L ^a   Bettaieb, A ^a   Solary, E ^a,c  

^a INSERM   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c HÔPITAL DU BOCAGE   (France)

Author keywords

Aging; Apoptosis; Caspase; Platelets; Storage

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE 3; CASPASE INHIBITOR; DIMETHYL SULFOXIDE; FAS ANTIGEN; THROMBOCYTE CONCENTRATE; THROMBOCYTE RECEPTOR;

APHERESIS; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL NUCLEUS; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKOCYTE; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; THROMBOCYTE MEMBRANE; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION;

EID: 0034777852     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402231     Document Type: Article

References (56)

1. Platelet activation during preparation of platelet concentrates: A comparison of the platelet-rich plasma and the buffy coat methods
2. The official requirements for platelet concentrates
3. The platelet storage lesion
4. Platelet activation may explain the storage lesion in platelet concentrates
5. Progressive platelet activation with storage: Evidence for shortened survival of activated platelets after transfusion
6. Studies with a monoclonal antibody against activated platelets: Evidence that a secreted 53:000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation
7. Circulating adhesion molecules in disease
8. Procoagulant expression in platelets and defects leading to clinical disorders
9. Alterations in Bcl-2/Bax protein levels in platelets form part of an ionomycin-induced process that resembles apoptosis
10. Activation of caspases triggered by cytochrome c in vitro
11. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner
12. Molecular characterization of mitochondrial apoptosis-inducing factor
13. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition
14. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins
15. Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1 -mediated caspase-9 activation and apoptosis
16. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
17. Two CD95 (APO/Fas) signalling pathways
18. Caspases: Intracellular signalling by proteolysis
19. Mammalian cell death proteases: A family of highly conserved aspartate specific cysteine proteases
20. Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis
21. Role of caspase in a subset of human platelet activation responses
22. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation
23. Programmed cell death and Bcl-2 protection in the absence of a nucleus
24. Cell nucleus and DNA fragmentation are not required for apoposis
25. Calpain-catalyzed cleavage and subcellular relocation of protein phosphotyrosine phosphatase 1B (PTP-1B) in human platelets
26. The mechanism of apoptosis in human platelets during storage
27. Mitochon drial release of caspase-2 and -9 during the apoptotic process
28. Caspases: Their intracellular localization and translocation during apoptosis
29. Flow cytometry: A clinical test of platelet function
30. White cell apoptosis in platelet concentrates
31. Glycosylphosphatidylinositol-anchor intermediates associate with triton-soluble membranes in subcellular compartments that include the endoplasmatic reticulum
32. Bcl-2 proteins: Regulators of apoptosis or of mitochondrial homeostasis?
33. BH3-only proteins - Essential initiators of apoptotic cell death
34. Constitutive death of platelets leading to scavenger receptor-mediated phagocytosis
35. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies
36. Improved maintenance of platelet in vivo viability during storage when using a synthetic medium with inhibitors
37. Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1
38. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
39. Involvement of capase-2 long isoform in Fas-mediated cell death of human leukemic cells
40. Specific proteolytic cleavage of poly (ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis
41. Different subcellular distribution of caspase-3 and caspase-7 following Fas-induced apoptosis in mouse liver
42. Proteolysis of fodrin (non-erythroid spectrin) during apoptosis
43. Limited proteolysis of protein kinase C subspecies by calcium-dependent neutral protease (calpain)
44. Bim: A novel member of the Bcl-2 family that promotes apoptosis
45. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with dynein motor complex
46. Proapoptotic Bcl-2 relative Bim is required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity
47. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1
48. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
49. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The TRAIL to non-toxic cancer therapeutics
50. The receptor for the cytotoxic ligang TRAIL
51. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
52. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
53. A novel receptor for Apo2L/TRAIL contains a truncated death domain
54. Characterization of two receptors for TRAIL
55. Anticancer agents sensitize tumor cells to TRAIL-mediated caspase-8 activation and apoptosis
56. From bench to clinic with apoptosis-based therapeutic agents